SBIR Grants Non Dilutive Funding Bootstrap Your Startup CompanyOctober 3, 2017
SBIR Funding to Bootstrap your Startup – Secrets and Lessons
Laura M. Hales, Ph.D., cofounder and Chief Business Officer of Extend Biosciences Inc.
Non-Dilutive Funding and Ways To Bootstrap Your Startup Company
Stephen Y. Chow, Esq., Partner, Burns & Levinson, LLP
SBIR Grants & Non Dilutive Funding – Perspective From a Proposal Writer and Principal Investigator
Dr. Jeffrey Everson, Founder of J.H. Everson Consulting
Starting a company to transform a great idea to a product or service can be fun and exciting. It usually requires lots of hard work and often and lots of money too. Entrepreneurs not blessed with a trust fund, wealthy relatives or a winning Powerball scratch ticket, have to get that money from somewhere. Venture Capital or Angel investors can be helpful, if the new company fits in with their investment strategy and interests, but this is expensive money that is very picky, usually impatient and can be as elusive as a winning lottery ticket.
Non-dilutive funding, generally in the form of grants from government agencies or private foundations, or even corporate partnerships, can give an entrepreneur the opportunity to launch a company and to build value without having to give up control or equity.
If equity investment ultimately becomes necessary, having built and demonstrated value can be quite beneficial in negotiations with investors.
During our October 3 meeting our panel will share their insights and experiences regarding non-dilutive funding – join us for inspiration and networking.
6:30-7:30 PM – Registration & networking
7:30-7:40 PM – ENET Chairman’s announcements
7:40-7:55 PM – E Minute – Up to 3 Startup companies’ presentations
7:55-8:45 PM – 3 expert speakers on the night’s topic
8:45-9:00 PM – Audience / Speakers Q & A
9:00-9:30 PM – Final networking including meeting speakers
Laura M. Hales, Ph.D. is a cofounder and Chief Business Officer of Extend Biosciences Inc., an emerging biotechnology company that is developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins.
At Extend Biosciences, Dr. Hales manages all of the outsourcing, operational and business development activities for the company. She has also been instrumental in obtaining the $6M+ in SBIR grants and other non-dilutive funding the company has received from multiple state and federal agencies.
Dr. Hales is also the Founder and Principal at The Isis Group, where her primary focus is to assist life science entrepreneurs in new business formation and non-dilutive funding efforts. Dr. Hales received her Ph.D. at the University of Illinois at Urbana-Champaign and was a postdoctoral fellow at Columbia University. She worked in the startup biotech industry for 9 years before co-founding Extend Biosciences.
Stephen Y. Chow, Esq., Partner, Burns & Levinson, LLP
Over three decades of practice, Attorney Stephen Y. Chow has developed numerous patent portfolios and strategies for a variety of industries including IT, chemical and life sciences enterprises, litigated patent, copyright, trademark, trade secret, antitrust, unfair competition, international trade, telecommunications and e-commerce cases before state and federal courts and agencies. Mr. Chow has coordinated or served as an expert in litigation before foreign tribunals. He has also advised manufacturers, telecommunications carriers, commercial exchanges and educational, financial and research institutions on commercial, legislative and regulatory matters, particularly in internal policies and development of new services and products, as well as in early-stage financing.
Mr. Chow sees himself as a strategist and trouble-shooter for technology companies in financial, governance and intellectual property disputes and development. In particular, he offers integrated patent, technology and business prosecution, assessment and enforcement with the commensurate benefits.
From 1995-2013, Mr. Chow taught corporate, intellectual property and litigation practice at Suffolk University Law School, including the perennial “Counseling Technology-Leading Emerging Enterprises,” and since then has been teaching a similar course at Boston University School of Law. In 1997, he was elected to the American Law Institute, for which he has been active on consultative committees on contract, corporate, employment, intellectual property, international and privacy law
Dr. Jeffrey Everson is the founder of J.H. Everson Consulting, where he assists clients in the pursuit of revenue generating opportunities by performing detailed technology and market studies based on the intersection of technologies, markets, environmental issues, and policies. This support includes white papers and proposals to commercial and government organizations, including the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
He specializes in Sensor Systems, Sensor Technology Development, and Collision Warning Systems for Roadway Vehicle Safety. Previously, he was Director of Business Development at Qinetiq North America, in Waltham, MA (previously Foster-Miller, Inc.). He started at Foster-Miller as a Senior Engineer at where he served as the principal investigator (PI) for multiple Small Business Innovation Research (SBIR) programs, including an inner city transit bus crash warning system, for which he won a national SBIR Tibbetts award.
Dr. Everson has a BS and MS in physics from Northeastern University with a minor in German and a PhD in physics from Boston College. For more information, please see www.JHEversonConsulting.com
Roger Frechette is Founder and Principal of New England PharmAssociates, LLC, a consultancy offering on-demand executive and business advisory services to life sciences enterprises. Dr. Frechette has been a volunteer with Boston ENET since 2014, and supports area start-ups as a mentor for MassBio’s MassCONNECT Program and the MTTC’s Platform Program.
Previously, Dr. Frechette was Co-Founder of MaxThera, an antibacterial drug discovery company funded exclusively through SBIR and US BioShield grants. MaxThera was sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Dr. Frechette was Project Director at Paratek Pharmaceuticals (Boston). At Paratek he led the team that discovered PTK0796 (currently in Phase III clinical trials) with strategic partner Glaxo-Wellcome. Previously, he was Associate Director of Chemistry at RiboGene (Hayward, CA). He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (J&J, Raritan, NJ).
Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wesleyan University and his BA in Chemistry from College of the Holy Cross.